Most cited papers from United Therapeutics (United States)
What are the most cited papers from United Therapeutics (United States)?
The most cited paper from United Therapeutics (United States) is "Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis" (Francis X. McCormack et al., 2011), with 1,131 citations. Next come "Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension" (831) and "Prediction of Chemical Carcinogenicity in Rodents from in Vitro Genetic Toxicity Assays" (817).
Showing 50 of 60 papers. Every paper with more than 85 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis Francis X. McCormack et al. · New England Journal of Medicine | 16 Mar 2011 | 1,131 |
| 2 | Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension Ronald J. Raymond, Alan L. Hinderliter, Park W. Willis et al. · Journal of the American College of Cardiology | Apr 2002 | 831 |
| 3 | Prediction of Chemical Carcinogenicity in Rodents from in Vitro Genetic Toxicity Assays Raymond W. Tennant, Barry H. Margolin, Michael D. Shelby et al. · Science | 22 May 1987 | 817 |
| 4 | CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation Jiehui Deng et al. · Cancer Discovery | 3 Nov 2017 | 801 |
| 5 | A model for microwave emission from vegetation‐covered fields Tianxiao Mo, Bhaskar Jyoti Choudhury, Thomas J. Schmugge et al. · Journal of Geophysical Research Atmospheres | 20 Dec 1982 | 750 |
| 6 | Genetically Modified Porcine-to-Human Cardiac Xenotransplantation Bartley P. Griffith, Corbin E. Goerlich, Avneesh Kumar Singh et al. · New England Journal of Medicine | 22 Jun 2022 | 708 |
| 7 | Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease Aaron B. Waxman, Ricardo Restrepo‐Jaramillo, Thenappan Thenappan et al. · New England Journal of Medicine | 13 Jan 2021 | 652 |
| 8 | Beraprost therapy for pulmonary arterial hypertension Robyn J. Barst, Michael D. McGoon, Vallerie V. McLaughlin et al. · Journal of the American College of Cardiology | Jun 2003 | 634 |
| 9 | A survey of interstellar molecular hydrogen. I Blair D. Savage, J. F. Drake, W. Budich et al. · The Astrophysical Journal | Aug 1977 | 625 |
| 10 | Effect of surface roughness on the microwave emission from soils Bhaskar Jyoti Choudhury, Thomas J. Schmugge, Alfred T. C. Chang et al. · Journal of Geophysical Research Atmospheres | 20 Sep 1979 | 624 |
| 11 | The promise of organ and tissue preservation to transform medicine Sebastian Eriksson Giwa et al. · Nature Biotechnology | Jun 2017 | 552 |
| 12 | Results of Two Cases of Pig-to-Human Kidney Xenotransplantation Robert A. Montgomery et al. · New England Journal of Medicine | 18 May 2022 | 501 |
| 13 | Remote sensing of soil moisture content, over bare field at 1.4 GHz frequency J. R. Wang, Bhaskar Jyoti Choudhury · Journal of Geophysical Research Atmospheres | 20 Jun 1981 | 487 |
| 14 | Observational, reference and model data on solar EUV, from measurements on AE‐E Hans E. Hinteregger, Katsura Fukui, Bruce R. Gilson · Geophysical Research Letters | Nov 1981 | 463 |
| 15 | Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) Victor F. Tapson, Fernando Torres, Fiona D. Kermeen et al. · CHEST Journal | 25 May 2012 | 379 |
| 16 | Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil R. J. Barst, Nazzareno Galiè, Robert Naeije et al. · European Respiratory Journal | 9 Aug 2006 | 336 |
| 17 | Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension Zhi‐Cheng Jing, Keyur H. Parikh, Tomás Pulido et al. · Circulation | 11 Jan 2013 | 326 |
| 18 | Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) Victor F. Tapson, Zhi‐Cheng Jing, Kai‐Feng Xu et al. · CHEST Journal | 17 May 2013 | 298 |
| 19 | The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT‐1001 in coeliac disease subjects: a proof of concept study Blake M. Paterson, Karen Manon Lammers, Marie‐Claire Arrieta et al. · Alimentary Pharmacology & Therapeutics | 19 Jun 2007 | 283 |
| 20 | The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension Stephen C. Mathai, Milo Alan Puhan, Diana L. Lam et al. · American Journal of Respiratory and Critical Care Medicine | 22 Jun 2012 | 277 |
| 21 | Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension Vallerie V. McLaughlin, Seán Gaine, Robyn J. Barst et al. · Journal of Cardiovascular Pharmacology | Feb 2003 | 233 |
| 22 | A parameterization of effective soil temperature for microwave emission Bhaskar Jyoti Choudhury, Thomas J. Schmugge, Tianxiao Mo · Journal of Geophysical Research Atmospheres | 20 Feb 1982 | 215 |
| 23 | Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension Dinesh Khanna, Heather S. Gladue, Richard N. Channick et al. · Arthritis & Rheumatism | 11 Sep 2013 | 212 |
| 24 | Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study Ciarán P. Kelly, P. H. R. Green, Joseph A. Murray et al. · Alimentary Pharmacology & Therapeutics | 19 Nov 2012 | 204 |
| 25 | Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial Jagdish Hiremath, S Thanikachalam, Keyur H. Parikh et al. · The Journal of Heart and Lung Transplantation | 18 Dec 2009 | 199 |
| 26 | Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer Jonathan S. Berek, Peyton T. Taylor, Alan N. Gordon et al. · Journal of Clinical Oncology | 30 Aug 2004 | 196 |
| 27 | Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers Kevin Laliberte, Carl P. Arneson, Roger Jeffs et al. · Journal of Cardiovascular Pharmacology | 8 Jul 2004 | 184 |
| 28 | Dry Powder Inhalers: An Overview Paul J. Atkins · Respiratory Care | Oct 2005 | 182 |
| 29 | Justification of specific genetic modifications in pigs for clinical organ xenotransplantation David K. C. Cooper, Hidetaka Hara, Hayato Iwase et al. · Xenotransplantation | 15 Apr 2019 | 181 |
| 30 | Pig-to-human heart xenotransplantation in two recently deceased human recipients Nader Moazami et al. · Nature Medicine | 24 Jul 2023 | 179 |
| 31 | A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Tolerability of Restylane Versus Zyplast for the Correction of Nasolabial Folds Rhoda S. Narins, Fredric S Brandt, JAMES LEYDEN et al. · Dermatologic Surgery | Jun 2003 | 178 |
| 32 | Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19 Zhenhua Li, Zhenzhen Wang, Phuong‐Uyen Dinh et al. · Nature Nanotechnology | 17 Jun 2021 | 178 |
| 33 | A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) Mercedeh Ghadessi, Rui Sammi Tang, Joey Tianyi Zhou et al. · Orphanet Journal of Rare Diseases | 12 Mar 2020 | 177 |
| 34 | Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer Jonathan S. Berek, Peyton T. Taylor, William Patrick McGuire et al. · Journal of Clinical Oncology | 16 Dec 2008 | 172 |
| 35 | Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer Craig M. Goodwin et al. · Cancer Research | 8 Nov 2022 | 171 |
| 36 | Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist Brendan J.R. Whittle, Adam M. Silverstein, David M. Mottola et al. · Biochemical Pharmacology | 27 Mar 2012 | 168 |
| 37 | Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension Alan L. Hinderliter, Park W. Willis, Walker A. Long et al. · The American Journal of Cardiology | Aug 1999 | 164 |
| 38 | Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial R. James White, Carlos Jerjes‐Sánchez, Gisela Martina Bohns Meyer et al. · American Journal of Respiratory and Critical Care Medicine | 25 Nov 2019 | 156 |
| 39 | Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study Steven D. Nathan, Aaron B. Waxman, Sudarshan Rajagopal et al. · The Lancet Respiratory Medicine | 29 Jun 2021 | 148 |
| 40 | A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder John H. Greist, James W. Jefferson, Kenneth A. Kobak et al. · International Clinical Psychopharmacology | Jun 1995 | 135 |
| 41 | Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits Bryan C. Quach et al. · Nature Communications | 3 Nov 2020 | 133 |
| 42 | Initial scalar magnetic anomaly map from MAGSAT R. A. Langel, Jeffrey D. Phillips, R. J. Horner · Geophysical Research Letters | Apr 1982 | 129 |
| 43 | Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression John Bisi, Jessica A. Sorrentino, Patrick J. Roberts et al. · Molecular Cancer Therapeutics | 29 Jan 2016 | 127 |
| 44 | Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1) Toufike Kanouni, Christophe Severin, Robert W. Cho et al. · Journal of Medicinal Chemistry | 9 Oct 2020 | 126 |
| 45 | Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension Jean‐Luc Vachiéry, Nicholas S. Hill, Diane L. Zwicke et al. · CHEST Journal | May 2002 | 125 |
| 46 | Lactate Dehydrogenase and the Diagnosis of Malaria Michael T. Makler, Robert C. Piper, Wilbur K. Milhous · Parasitology Today | Sep 1998 | 112 |
| 47 | Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials Raymond L. Benza, Mardi Gomberg‐Maitland, Robert Naeije et al. · The Journal of Heart and Lung Transplantation | 6 May 2011 | 105 |
| 48 | PC-BEIS: A Personal Computer Version of the Biogenic Emissions Inventory System Thomas E. Pierce, Paul S. Waldruff · Journal of the Air & Waste Management Association | Jul 1991 | 102 |
| 49 | Transplantation of a genetically modified porcine heart into a live human Bartley P. Griffith et al. · Nature Medicine | 8 Jan 2025 | 99 |
| 50 | A Golgi-targeting fluorescent probe for labile Fe( ii ) to reveal an abnormal cellular iron distribution induced by dysfunction of VPS35 Tasuku Hirayama, Masatoshi Inden, Hitomi Tsuboi et al. · Chemical Science | 25 Nov 2018 | 96 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.